Vericel Corporation $VCEL Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. trimmed its holdings in shares of Vericel Corporation (NASDAQ:VCEL) by 4.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,145,259 shares of the biotechnology company’s stock after selling 48,500 shares during the period. Federated Hermes Inc.’s holdings in Vericel were worth $48,731,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Conestoga Capital Advisors LLC grew its holdings in Vericel by 19.5% during the second quarter. Conestoga Capital Advisors LLC now owns 2,463,590 shares of the biotechnology company’s stock worth $104,826,000 after acquiring an additional 401,990 shares during the period. Invesco Ltd. lifted its holdings in Vericel by 1.6% in the first quarter. Invesco Ltd. now owns 2,273,494 shares of the biotechnology company’s stock valued at $101,443,000 after acquiring an additional 35,345 shares during the period. Geneva Capital Management LLC boosted its position in shares of Vericel by 30.7% during the 2nd quarter. Geneva Capital Management LLC now owns 1,784,927 shares of the biotechnology company’s stock worth $75,949,000 after purchasing an additional 419,183 shares in the last quarter. Congress Asset Management Co. grew its stake in shares of Vericel by 18.0% during the 2nd quarter. Congress Asset Management Co. now owns 1,742,324 shares of the biotechnology company’s stock worth $74,136,000 after purchasing an additional 265,606 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Vericel by 5.8% during the 1st quarter. Wellington Management Group LLP now owns 1,363,644 shares of the biotechnology company’s stock worth $60,846,000 after purchasing an additional 74,723 shares during the period.

Vericel Price Performance

VCEL stock opened at $37.30 on Tuesday. The company’s 50 day simple moving average is $36.64 and its 200-day simple moving average is $37.45. Vericel Corporation has a 12 month low of $29.24 and a 12 month high of $63.00. The firm has a market capitalization of $1.89 billion, a PE ratio of 155.42 and a beta of 1.20.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.12. The firm had revenue of $67.50 million during the quarter, compared to the consensus estimate of $64.57 million. Vericel had a return on equity of 4.30% and a net margin of 5.06%.The company’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) EPS. As a group, sell-side analysts anticipate that Vericel Corporation will post 0.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. BTIG Research downgraded shares of Vericel from a “buy” rating to a “neutral” rating in a report on Wednesday, September 17th. Zacks Research downgraded shares of Vericel from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Weiss Ratings reissued a “hold (c-)” rating on shares of Vericel in a research note on Tuesday, November 25th. Truist Financial reaffirmed a “buy” rating and issued a $50.00 price objective (up from $41.00) on shares of Vericel in a research note on Monday, November 10th. Finally, Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $58.75.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.